Drugs / Glecaprevir/Pibrentasvir
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT03981211 | Feb 2021 → Dec 2024 | cirrhosis of liver, hepatitis C virus infection | Kirby Institute | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Glecaprevir/Pibrentasvir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03981211 ↗ |
| Known as | G/P | “A) 30 patients will immediately commence treatment whilst an inpatient of G/P (glecaprevir/pibrentasvir) with continuation of therapy and follow-up in viral hepatitis services...” NCT03981211 ↗ |
| Route | Oral | “Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet” NCT03981211 ↗ |